Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)

Department of Health and Human Services National Institutes of Health

Type

Research/project funding

Posted on

24 March 2023

Application Deadline

13 June 2025

Reference Number

RFA-CA-23-028

The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents.
Categories: Education, Health.

More Information

Visit Website

Type

Research/Project Funding

Posted on

24 March 2023

Application Deadline

13 June 2025

Reference Number

RFA-CA-23-028

Turn On Deadline Reminders

, United States

Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)

Research/project funding

24 March 2023

13 June 2025

RFA-CA-23-028

Research/Project Funding

24 March 2023

13 June 2025

RFA-CA-23-028

Also Interesting

Notice of NHLBI Participation in PAR-25-233 "Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)"

Notice of Extension of the Expiration Date for RFA-OD-22-013 "Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed)"

Notice of Early Expiration of RFA-EB-22-002, "HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)"